KIN-1902 ( DrugBank: - )


1 disease
告示番号疾患名(ページ内リンク)臨床試験数
84サルコイドーシス1

84. サルコイドーシス


臨床試験数 : 149 薬物数 : 202 - (DrugBank : 78) / 標的遺伝子数 : 66 - 標的パスウェイ数 : 169
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2021-004794-31-NL
(EUCTR)
01/07/202210/05/2022A study to Assess the Efficacy and Safety of Namilumab in subjects with lung inflammatory diseaseA Randomized, Double-blind, Placebo-controlled Phase 2 Study with Open-label Extension to Assess the Efficacy and Safety of Namilumab in Subjects with Chronic Pulmonary Sarcoidosis - Resolve-Lung chronic pulmonary sarcoidosis
MedDRA version: 20.0;Level: PT;Classification code 10037430;Term: Pulmonary sarcoidosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
Product Name: Namilumab
Product Code: KIN-1902
INN or Proposed INN: NAMILUMAB
Kinevant Sciences GmbHNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
100Phase 2France;United States;Belgium;Turkey;Germany;Netherlands;United Kingdom